Clinical trials

5

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis

This study was conducted to determine the effect of Umbilical Cord Mesenchymal Stem Cell (UC-MSC) and Secretome in severe ARDS patients. The study is a randomized control trial - double blind, which has 3 arms intervention namely, Control treatment, UC-MSC treatment, and UC-MSC and Secretome treatment.

Participants needed: 15
Trial details
Phase: Phase 1, Phase 2Age: 40+Biological sex: AllType: InterventionalSponsor: PT. Prodia Stem Cell IndonesiaUpdated: Feb 27, 2026Locations: 1
Eligibility criteria

Male or female at least 40 years old when the Informed Consent Form (ICF) is sig... [+2]

A pregnant woman is proven by a pregnancy test. [+5]

Status: Not yet recruiting

Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II

The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells. Each group consists of 30 subjects. All groups will be transplanted via the peribulbar route. All groups will be observed until six months.

Participants needed: 30
Trial details
Phase: Phase 2, Phase 3Age: 18-65Biological sex: AllType: InterventionalSponsor: PT. Prodia Stem Cell IndonesiaUpdated: Feb 25, 2026Locations: 1
Eligibility criteria

Visus more than 20/100 [+5]

Pregnant or nursing women [+5]

Status: Not yet recruiting

Long-term Safety of UC-MSC Transplantation in Patients With Retinitis Pigmentosa

The study will perform to follow-up UC-MSCs and CM transplantation. 18 patients will be called back to be examined after 5 years of UC-MSC and/or CM transplantation.

Participants needed: 18
Trial details
Age: 18-65Biological sex: AllType: ObservationalSponsor: PT. Prodia Stem Cell IndonesiaUpdated: Feb 25, 2026Locations: 2
Eligibility criteria

Visual field defects at the initial examination with Humphrey perimetry are betw... [+3]

Pregnant or nursing women [+5]

Status: Recruiting

Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients

This study aims to compare the effectiveness of secretome injection and intradermal platelet-rich plasma (PRP) injection on hair density and the terminal-to-vellus hair ratio in patients with androgenetic alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital.

Participants needed: 40
Trial details
Phase: Phase 1, Phase 2Age: 25-59Biological sex: AllType: InterventionalSponsor: PT. Prodia Stem Cell IndonesiaUpdated: Feb 24, 2026Locations: 1
Eligibility criteria

Male patients with androgenetic alopecia, aged 25 to 59 years, with clinical pre... [+5]

Participants who are unable to speak or understand Indonesian and/or are unwilli... [+7]

Status: Recruiting

Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial

The goal of this clinical trial is to evaluate the safety and efficacy of a single intra-renal injection of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) in adults with diabetic nephropathy aged 40 to 65 years. The primary questions the study aims to answer are: 1. Is UC-MSC therapy safe and well-tolerated when administered intra-renally in patients with diabetic nephropathy? 2. Does UC-MSC therapy improve kidney function and modulate inflammatory markers over a 12-month follow-up-period? This is a single-arm, open-label, prospective clinical trial. Participants will receive a one-time intra-renal injection of UC-MSC at a dose of 1 x 10⁶ cells/kg body weight. Participants will attend scheduled follow-up visits at 1, 3, 6, 9, and 12 months post-injections for evaluation of: 1. Renal function (eGFR, serum creatinine, and urine albumin-creatinine ratio) 2. Inflammatory markers (TNF-α, IL-10) 3. Safety outcomes including early and late adverse events The results will be compared to baseline measurements to assess changes after the intervention. If there is a comparison group: Researchers will compare \[arm information\] to see if \[insert effects\]. Participants will \[describe the main tasks participants will be asked to do, interventions they'll be given and use bullets if it is more than 2 items\].

Participants needed: 10
Trial details
Phase: Phase 1, Phase 2Age: 30-65Biological sex: AllType: InterventionalSponsor: PT. Prodia Stem Cell IndonesiaUpdated: Feb 9, 2026Locations: 1
Eligibility criteria

Diagnosed with Type 2 Diabetes Mellitus (T2DM) [+8]

Active malignancy or history of cancer [+6]